169 related articles for article (PubMed ID: 14560055)
1. Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering.
Sandström K; Xu Z; Forsberg G; Nygren PA
Protein Eng; 2003 Sep; 16(9):691-7. PubMed ID: 14560055
[TBL] [Abstract][Full Text] [Related]
2. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
[TBL] [Abstract][Full Text] [Related]
3. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
4. CD80 and CD86 are not equivalent in their ability to induce the tyrosine phosphorylation of CD28.
Slavik JM; Hutchcroft JE; Bierer BE
J Biol Chem; 1999 Jan; 274(5):3116-24. PubMed ID: 9915850
[TBL] [Abstract][Full Text] [Related]
5. Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion.
Ueda Y; Levine BL; Huang ML; Freeman GJ; Nadler LM; June CH; Ward SG
Int Immunol; 1995 Jun; 7(6):957-66. PubMed ID: 7577804
[TBL] [Abstract][Full Text] [Related]
6. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
[TBL] [Abstract][Full Text] [Related]
7. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins.
van Wijk F; Nierkens S; de Jong W; Wehrens EJ; Boon L; van Kooten P; Knippels LM; Pieters R
J Immunol; 2007 Jun; 178(11):6894-900. PubMed ID: 17513738
[TBL] [Abstract][Full Text] [Related]
8. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
van der Merwe PA; Bodian DL; Daenke S; Linsley P; Davis SJ
J Exp Med; 1997 Feb; 185(3):393-403. PubMed ID: 9053440
[TBL] [Abstract][Full Text] [Related]
9. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
[TBL] [Abstract][Full Text] [Related]
10. CD80 cytoplasmic domain controls localization of CD28, CTLA-4, and protein kinase Ctheta in the immunological synapse.
Tseng SY; Liu M; Dustin ML
J Immunol; 2005 Dec; 175(12):7829-36. PubMed ID: 16339518
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
[TBL] [Abstract][Full Text] [Related]
12. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.
Qureshi OS; Zheng Y; Nakamura K; Attridge K; Manzotti C; Schmidt EM; Baker J; Jeffery LE; Kaur S; Briggs Z; Hou TZ; Futter CE; Anderson G; Walker LS; Sansom DM
Science; 2011 Apr; 332(6029):600-3. PubMed ID: 21474713
[TBL] [Abstract][Full Text] [Related]
13. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
[TBL] [Abstract][Full Text] [Related]
14. CD28 co-stimulatory regimes differ in their dependence on phosphatidylinositol 3-kinase: common co-signals induced by CD80 and CD86.
Cefai D; Cai YC; Hu H; Rudd C
Int Immunol; 1996 Oct; 8(10):1609-16. PubMed ID: 8921441
[TBL] [Abstract][Full Text] [Related]
15. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
Caux C; Vanbervliet B; Massacrier C; Azuma M; Okumura K; Lanier LL; Banchereau J
J Exp Med; 1994 Nov; 180(5):1841-7. PubMed ID: 7525840
[TBL] [Abstract][Full Text] [Related]
16. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.
Metzler WJ; Bajorath J; Fenderson W; Shaw SY; Constantine KL; Naemura J; Leytze G; Peach RJ; Lavoie TB; Mueller L; Linsley PS
Nat Struct Biol; 1997 Jul; 4(7):527-31. PubMed ID: 9228944
[TBL] [Abstract][Full Text] [Related]
17. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
[TBL] [Abstract][Full Text] [Related]
18. T cells: A proliferation of costimulatory molecules.
Mueller DL
Curr Biol; 2000 Mar; 10(6):R227-30. PubMed ID: 10744968
[TBL] [Abstract][Full Text] [Related]
19. Requirements for stimulation or anergy induction in alloreactive human T cell clones.
Pawelec G; Kalbacher H; Pohla H; Boshell M; Max H; Friccius H; Adibzadeh M; Hambrecht A; Sansom D
Cell Immunol; 1994 Oct; 158(1):241-52. PubMed ID: 7522128
[TBL] [Abstract][Full Text] [Related]
20. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen.
Hayden MS; Grosmaire LS; Norris NA; Gilliland LK; Winberg G; Tritschler D; Tsu TT; Linsley PS; Mittler RS; Senter PD; Fell HP; Ledbetter JA
Tissue Antigens; 1996 Oct; 48(4 Pt 1):242-54. PubMed ID: 8946677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]